>> As each day passes I become more concerned that GENR's management team is hurting the companies chances for getting Squalamine to market soon than later. <<
That’s an understandable, though not especially cerebral, reaction. rwwine, please do not take my comments personally; however, I have observed that posts about these concerns pop up often on days when the stock is declining, but rarely if ever on days when the stock is appreciating.
If you believe that GENR’s management is competent and you believe that GENR’s management is honest (i.e. that they have shareholder value in mind), then they ought to be entitled to the benefit of the doubt.
Management's track record over the past year hasn’t been completely spotless (the financings have been less than ideal). But the track record has been very good overall. Therefore, I am inclined to believe that a delay in consummating a partnership is a delay that will ultimately prove to be in our best interests. Regards, Dew
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
